The US Food and Drug Administration (FDA) approved zuranolone last August, with the trade name Zurzuvae. The first oral medication indicated to treat postnatal depression.
Zuranolone is a drug that acts as a progesterone derivative. This is a hormone that acts on GABA-A receptors and has been found to be involved in mental disorders such as anxiety and depression. During the postnatal period, there is a sudden drop in progesterone levels, which could be the mechanism by which some women’s depressive symptoms begin.